Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16871014 | 0.86 | MCHR1 (0.44) | BCHESMN1; SMN2ALDH1A1 | |
| SCHEMBL16871129 | 0.84 | GSK3B (0.40) | BCHEACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11326295 | 0.77 | SMN1; SMN2 (0.40) | BCHEACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11073006 | 0.71 | BCHE (0.41) | BCHEACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL16871131 | 0.64 | MEN1 (0.42) | BCHEACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28168110 | 0.64 | NOX1 (0.41) | BCHEACHEMEN1KMT2ALMNA | |
| SCHEMBL27893554 | 0.63 | GSK3B (0.41) | BCHEACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL28131846 | 0.62 | NOX1 (0.42) | BCHEACHEMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7592555 | 0.61 | MEN1 (0.53) | BCHEACHEMEN1KMT2AALDH1A1 | |
| SCHEMBL3386305 | 0.60 | BCHE (0.41) | BCHEACHEMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150183772-A1 | ALKYLATION OF AZOLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150183772-A1 | ALKYLATION OF AZOLES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2015-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150183772-A1 | ALKYLATION OF AZOLES | AKR1C3, DCXR, AKR1C2 | BCHE 4026/4885ACHE 4220/4885MEN1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.